Compassionate Use Program for PV-10

Compassionate use programs provide experimental therapeutics to patients prior to final FDA approval. The compassionate use program for PV-10 was conducted through June 2016 at locations in the US and Australia, and was available for cancer indications that did not involve visceral organs and were not subject to enrollment in ongoing clinical trials. More than 180 patients participated in the expanded access study.

Although the expanded access study has ended, further information about the study, titled "Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors", is available at the U.S. National Institute of Health's website.